We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

62 hedge funds and large institutions have $527M invested in Acceleron Pharma in 2013 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,397% more capital invested

Capital invested by funds: $11.7M → $527M (+$515M)

1,350% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 4

675% more funds holding

Funds holding: 8 → 62 (+54)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

Holders
62
Holders Change
+54
Holders Change %
+675%
% of All Funds
1.8%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.09%
New
58
Increased
2
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$51.1M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$43.5M
3
DVC
Deer VII & Co
New York
+$26.7M
4
JP Morgan Chase
JP Morgan Chase
New York
+$18.5M
5
Franklin Resources
Franklin Resources
California
+$14.4M

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.56M
2
ICAP
Independence Capital Asset Partners
Colorado
-$835K
3
MCM
Mazama Capital Management
Oregon
-$445K
4
FSA
Franklin Street Advisors
North Carolina
-$43.4K
5
SSG
Summit Securities Group
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCIM
26
TIAA CREF Investment Management
New York
$1.94M +$1.18M +49,070 New
SONJCPFA
27
State of New Jersey Common Pension Fund A
New Jersey
$1.7M +$1.04M +43,000 New
BG
28
BlackRock Group
United Kingdom
$1.67M +$1.02M +42,100 New
Principal Financial Group
29
Principal Financial Group
Iowa
$1.6M +$975K +40,400 New
Morgan Stanley
30
Morgan Stanley
New York
$1.57M +$957K +39,636 New
EI
31
EAM Investors
California
$1.5M +$914K +37,871 New
Geode Capital Management
32
Geode Capital Management
Massachusetts
$1.31M +$799K +33,121 New
BBA
33
Baker Bros. Advisors
New York
$1.19M +$724K +30,000 New
GPCM
34
Granite Point Capital Management
Massachusetts
$1.19M +$724K +30,000 New
Bank of New York Mellon
35
Bank of New York Mellon
New York
$886K +$540K +22,367 New
RFC
36
Russell Frank Company
Washington
$840K +$443K +18,345 New
BIM
37
BlackRock Investment Management
Delaware
$668K +$407K +16,869 New
FSA
38
Franklin Street Advisors
North Carolina
$574K -$43.4K -1,800 -11%
Charles Schwab
39
Charles Schwab
California
$554K +$337K +13,975 New
California State Teachers Retirement System (CalSTRS)
40
California State Teachers Retirement System (CalSTRS)
California
$459K +$280K +11,600 New
TD Asset Management
41
TD Asset Management
Ontario, Canada
$440K +$268K +11,100 New
SAM
42
Sectoral Asset Management
Quebec, Canada
$389K +$237K +9,827 New
PAM
43
Panagora Asset Management
Massachusetts
$378K +$231K +9,556 New
TAM
44
Tocqueville Asset Management
New York
$376K +$229K +9,500 New
MLICM
45
Metropolitan Life Insurance Company (MetLife)
New York
$334K +$204K +8,439 New
TC
46
TFS Capital
Pennsylvania
$323K +$197K +8,149 New
TA
47
Teachers Advisors
New York
$287K +$175K +7,260 New
NSEDCP
48
NJ State Employees Deferred Compensation Plan
New Jersey
$277K +$169K +7,000 New
Citigroup
49
Citigroup
New York
$207K +$126K +5,209 New
CS
50
Credit Suisse
Switzerland
$207K +$126K +5,229 New
1
2
3

XLRN Hedge Fund Activity: Q4 2013 in Review

62 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2013, worth a combined $527M — up 4,397% from $11.7M a quarter earlier.

Buyers outnumbered sellers: 58 funds opened new XLRN positions and 4 closed out — a net gain of 54 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $51.1M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.56M sold.

  • 62 institutional investors held Acceleron Pharma (XLRN) as of Q4 2013, up from 8 in Q3 2013.
  • Funds reported $527M of Acceleron Pharma stock for Q4 2013, up 4,397% quarter-over-quarter.
  • 58 funds opened new Acceleron Pharma positions in Q4 2013 and 4 closed out, a net change of +54 holders.
  • The largest Acceleron Pharma buyer in Q4 2013 was OrbiMed, an estimated $51.1M added.
  • The largest Acceleron Pharma seller in Q4 2013 was Alyeska Investment Group, an estimated $1.56M sold.

Based on aggregated 13F filings for Q4 2013.